Eventually, the second patient manifested a better clinical outcome than the first.<h4>Conclusion</h4>These results provide supporting evidence that KRAS exon 3 (R68S) mutations may be associated with Osimertinib resistance in lung adenocarcinoma patients. This evidence concerns the gene KRAS and lung adenocarcinoma.